[144] Fabrinet SEC Filing

Rhea-AI Filing Summary

Fabrinet (symbol FN) filed a Form 144 reporting a proposed sale of 9,000 ordinary shares through Citigroup Global Markets on the NYSE, with an aggregate market value of $3,009,240. The shares were acquired the same day, listed as restricted stock vesting from Fabrinet and paid as compensation. The filer reports no securities sold in the past three months and affirms they are not aware of any undisclosed material adverse information about the issuer. The notice identifies the sale as to be executed approximately on 09/02/2025.

Positive

• Transaction arises from restricted stock vesting, indicating the shares were received as compensation rather than purchased for speculative resale.
• No reported sales in the past three months, which helps demonstrate this is not part of frequent insider selling.

Negative

• None.

Insights

Securities Analyst

TL;DR Routine officer/insider sale from restricted stock vesting; small relative volume, limited market impact.

The filing discloses a planned sale of 9,000 ordinary shares valued at $3,009,240 executed via Citigroup on the NYSE. These shares were acquired the same day through restricted stock vesting as compensation from Fabrinet, indicating this is a compensation-related disposition rather than a sales-triggered liquidity event. With 35,729,581 shares outstanding, the block represents a very small fraction of float, suggesting limited immediate pricing impact. The filer also certifies no undisclosed material adverse information.

Corporate Governance Expert

TL;DR Disclosure aligns with Rule 144 requirements; demonstrates compliance with insider sale reporting and compensation accounting.

The notice explicitly ties the acquisition to restricted stock vesting and lists the nature of payment as compensation, which clarifies the transaction's origin. The absence of other sales in the prior three months and the accuracy of broker and market details support regulatory compliance. This is a routine filing that documents an insider monetizing vested compensation rather than signaling governance concerns or unusual insider activity.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary Shares	Citigroup Global Markets, Inc. 390 Greenwich St. New York NY 10013	9000	3009240.00	35729581	09/02/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares	09/02/2025	Restricted stock vesting	FABRINET			9000	09/02/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the Form 144 for Fabrinet (FN) report?

The form reports a proposed sale of 9,000 ordinary shares of Fabrinet.

How much are the 9,000 Fabrinet shares worth in the filing?

The aggregate market value is listed as $3,009,240.00.

How were the shares acquired according to the Form 144?

The shares were acquired on 09/02/2025 via restricted stock vesting from Fabrinet and paid as compensation.

Which broker will handle the sale reported in the Form 144?

The listed broker is Citigroup Global Markets, Inc. with an address at 390 Greenwich St., New York, NY.

When is the sale expected to take place?

The form lists the approximate date of sale as 09/02/2025 on the NYSE.